NCT04690608View on ClinicalTrials.gov

Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

February 1, 2025

Conditions

Retinal Edema

Interventions

DRUG

Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1

suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion

Trial Locations (1)

31111

Tanta University, Tanta

All Listed Sponsors

lead

Tanta University

OTHER

NCT04690608 - Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy | Biotech Hunter | Biotech Hunter